Women with pathogenic variants (PVs) in BRCA1 and BRCA2 (henceforth called ‘PV carriers’) are at high risk of developing breast cancer (BC) and ovarian cancer.1 However, BC risks for PV carriers vary by family history (FH) and by other genetic, lifestyle, hormonal and reproductive factors which can result in variability in the individualised BC risk assessment.2–5 Providing more personalised BC risks will enable informed decision-making for the clinical management of BC risk, for example, opting for bilateral risk-reducing mastectomy and its timing. Here, BRCA1 is linked to breast cancer.